Analysis of:
A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular Edema (www.ophsource.org)
This Phase III Clinical Trial clearly shows that focal grid laser is better than steroids in the management of Diabetic Macular Edema (DME). This reaffirms laser as the current gold standard in the management of DME and casts doubts on numerous treatment modalities in the pipeline that use steroids...
Analysis of:
Johnson & Johnson Vision Care Announces First Daily Disposable Silicone Hydrogel at BCLA (www.cltoday.com)
This new lens represents a marriage of two important technologies in modern contact lens use; oxygen trasmissibility and convenience in wearing. This has the potential to become a significant portion of the contact lens market.
Analysis of:
LASIK Worries? Some May See Better with Alternatives (www.washingtonpost.com)
The FDA report and scrutiny of LASIK complaints reveals what consientious LASIK surgeons have known for years: Not everyone who walks through your doors is a good lasik candidate and you should not laser everyone. About 1 out of 4 patients that consider lasik are actually good candidates...
Analysis of:
New model of mini glaucoma shung significantly lowers IOP (www.osnsupersite.com)
A new model of the increasing popular Ex-Press Shunt is quite effective in an early study. Its is quite safe and effective; and simpler substitute for trabeculectomy. It could be the first line in the surgical management of glaucoma.
Analysis of:
Injectable glaucoma drug shown to reduce IOP in clinical study (www.osnsupersite.com)
Alcon (ACL) reported positive interim results for their injectable medication for glaucoma. A single injection of anecortave acetate resulted in control of IOP at the three month follow up. This could be a promising medication for IOP control in glaucoma.
Analysis of:
Pilot trial for toric correction with light-adjustable lens yields promising early results (ophthalmologytimes.modernmedicine.com)
The light adjustable lens is a lens implant that is placed in the eye like a tradition intraocular lens during cataract surgery. The unique difference is that it can be treated with a special light after surgical implant (weeks to months later) to correct any residual refractive errors or to fine...
Analysis of:
MacuSight Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration (pharmalive.com)
Sicrolimus is a novel agent that has a broad range of activities that is entering the Ophthalmic Arena. Phase I Data has shown its safety profile in treating two large markets: Age Related Macular Degeneration and Diabetic Macular Edema. Given its success in cardiology, it is a promising...
Analysis of:
Bausch & Lomb Announces Positive Clinical Results for Zylet in a Comparison of Safety and Efficacy with Tobradex in the Treatment of Blepharokeratoconjunctivitis (pharmalive.com)
This study shows that Bausch and Lomb's Zylet is as good and safer than Alcon's Tobradex for the management of Blepharitis. Blepharitis is a large problem affecting many patients. This could be a large market opportunity.
Analysis of:
Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma (www.pipelinereview.com)
Biovitrum reports Phase II results of its new glaucoma medication. Although the mechanism of action of this glaucoma drug is novel and targets the site of disease in glaucoma, its clinical results are very disappointing. A 10% reduction in intraocular pressure is not enough to make a clinical...
Analysis of:
Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial (www.pipelinereview.com)
The CATT Trial will prospectively compare lucentis and avastin head to head in the management of Age Related Macular Degeneration. Lucentis costs 40X more than Avastin for ocular dosing; and many suspect that they both are similiar in efficacy. If CATT confirms this, it sink Lucentis Sales...